Lenalidomida Sandoz (Lenalidomide)

Lenalidomide binds to the cereblon component of the CRL4^CRBN E3 ubiquitin ligase complex, changing its substrate specificity. This triggers ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, leading to reduced malignant cell proliferation, enhanced immune‑mediated tumor cell killing, inhibition of angiogenesis, and modulation of cytokine production.

The dosage of Lenalidomida Sandoz is individualized and must be determined by a qualified prescriber based on the specific indication, patient characteristics, renal and hepatic function, and concomitant therapies. Healthcare professionals will calculate the appropriate dose and schedule according to current clinical guidelines and the patient’s therapeutic response.

Lenalidomida Sandoz is classified as pregnancy category X, meaning it is contraindicated during pregnancy because it can cause fetal harm. Women of childbearing potential must use effective contraception before, during, and after treatment. The drug is also not recommended for breastfeeding mothers, as it may be excreted in breast milk and affect the infant.

To place an order, visit the product page for Lenalidomida Sandoz on gnhindia.com and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Lenalidomida Sandoz belongs to the immunomodulatory drug (IMiD) class, similar to thalidomide and pomalidomide. Compared with thalidomide, lenalidomide generally offers a more favorable safety profile, especially regarding peripheral neuropathy, while retaining anti‑angiogenic and immunomodulatory activity. Pomalidomide is a newer IMiD with potency in certain refractory cases, but lenalidomide remains a standard first‑line option for the approved indications.

Lenalidomida Sandoz should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains tightly closed until use. Do not store in a refrigerator or freezer, as the formulation is designed for room‑temperature stability.

Lenalidomida Sandoz is taken orally, usually as a whole tablet or capsule, with or without food, as directed by the prescribing physician. Patients should swallow the dosage form whole with a glass of water and follow any specific timing instructions related to other medications or meals to optimize absorption and minimize gastrointestinal irritation.

The most serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), severe cutaneous reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, secondary primary malignancies, and significant hematologic toxicities like neutropenia and thrombocytopenia. Patients should be monitored regularly for signs of infection, bleeding, skin changes, and new cancer development.

Lenalidomida Sandoz should not be used by pregnant women or women who may become pregnant, due to its teratogenic potential. It is also contraindicated in patients with severe renal or hepatic impairment unless dose adjustments are made under specialist supervision. Individuals with a history of severe hypersensitivity to lenalidomide or any component of the formulation should avoid its use.